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Abstract
Ocular adnexa MALT-lymphomas represent approximatively 5-15% of all extranodal lymphomas. Almost 75% of
OAMLs are localized in orbital fat, while 25% of cases involves conjunctive. MALT-lymphomas often recognize
specific environmental factors responsible of lymphoma development and progression. In particular as Helicobacter
pylori in gastric MALT lymphomas, other bacterial infections have been recognized related to MALT lymphomas in
specific site. Recently Chlamydia psittaci has been identified in Ocular Adnexa MALT lymphomas, with variable
frequence dependently from geographic areas. Thus bacterial infection is responsible of clonal selection on
induced MALT with subsequent lymphoma development. Moreover Chlamydia psittaci could promote
chromosomal aberration either through genetic instability as a consequence of induced proliferation and probably
through DNA oxidative damage. The most common translocation described in MALT lymphomas affects NF-kB
pathway with a substantial antiapoptotic effect. Several therapeutic approaches are now available, but the use of
antibiotic-therapy in specific cases, although with conflicting results, could improve the treatment of ocular adnexa
MALT lymphomas. In this review we analyse the most relevant features of Ocular adnexa MALT lymphomas,
underlining specific biological characteristics mainly related to the potential role of Chlamydia psittaci in
lymphomagenesis.
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Background
Non-Hodgkin’s lymphomas represent the most common
ocular adnexa neoplasm [1]. Approximately accounting 5-
15% of all extranodal lymphomas localize at ocular adnexa,
including the conjunctiva, the lachrymal gland, the orbital
fat, the eyelid and the lachrymal sac [2]. In Western coun-
tries Marginal zone B-cell lymphoma of mucosa-associated
lymphoid tissue (MALT)-type accounts 50-78% of all ocu-
lar lymphomas, while in Japan and Korea the relative fre-
quence is much higher [3]. It has been recorded that
Ocular Adnexal MALT Lymphoma (OAML) increases by
more than 6% for year. These data are only partially
explained by the development of recent new lymphoma
classification and improvement of diagnostic approaches
[4].
MALT-lymphomas represent a wide range of extranodal
lymphomas that often recognize environmental factors
driving to specific genes deregulation. Interestingly, envir-
onmental factors are specifically related to sites of acquired
MALT development and furthermore the deregulated
genes, even if involved in the NF-kB pathway, share differ-
ent distribution in extranodal sites [5,6]. Among environ-
mental factors, some bacterial infections have been found
associated to MALT lymphomas of specific anatomic dis-
tricts, such as H. pylori in gastric MALT lymphoma,
C. Jejuni in intestinal MALT lymphoma and Borrelia Burg-
doferi in cutaneous B cell lymphoma [6-10]. Recently Chla-
mydia psittaci (Cp) has been identified in OAML [11-25].
Chromosomal aberrations involving mainly MALT1 and
bcl10 genes with consequent deregulation of their gene
expression are commonly observed in MALT lymphomas,
but with different distribution dependently from specific
anatomic regions, being t(11;18) more frequent in gastric
MALT lymphomas and t (14;18) in extragastric MALT
* Correspondence: renfr@yahoo.com
1Pathology Unit, National Cancer Institute “Giovanni Pascale”, Naples, Italy
Full list of author information is available at the end of the article
Collina et al. Infectious Agents and Cancer 2012, 7:8
http://www.infectagentscancer.com/content/7/1/8
© 2012 Collina et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.lymphoma [26-29]. Moreover environmental and biological
features show a relevant variability also related to geo-
graphic area. In fact Cp frequence in OAML has been
described with difference frequence all over the world
(Table 1) [11-25].
Thus this variability reflects different therapeutic strate-
gies, that apart conventional chemotherapy and radiother-
apy, are also based on specific targets or biomarkers useful
to predict therapeutic response [30].
Clinical features
Almost 75% of OAMLs are localized in orbital fat, while
25% of cases involves conjunctive [19,31-34]. Bilateral
involvement has been described in 15% of OAMLs
[19,31-34]. It arises after fourth decade, more frequently in
female [19,31-34]. 38% of patients show at least one extra-
orbital site with lymphoma localization at accurate staging
of OAML [35] In some cases autoimmune disorders are
concomitant [36].
Clinical presentation depends upon involved orbital
region, being exophthalmos (27% of cases), palpable mass
(19%), eyelid ptosis (6%), diplopia (2%), eyelid nodule,
orbital edema, epiphora and a variable degree of impaired
ocular motility the most frequent signs and symptoms for
orbital fat lymphomas, while ‘salmon red patch’ is the
most common feature of conjunctival lymphomas
[18,30-33]. Rarely impairment of extraocular muscle and
infiltration of eyes have been recorded [37]. Diagnosis
requires integrated study through computed tomography,
magnetic resonance and imaging (MRI) and A- and B-
scan orbital ultrasonography.
OAML patients exhibit a favorable outcome, when
adequately treated [19,38]. Nodal involvement (< 5% of
cases), systemic symptoms (1%), increased lactate dehy-
drogenase serum levels (1%) and non-conjunctival sites
a r ec o n s i d e r e dn e g a t i v ep r o g n o s t i cf a c t o r s[ 1 8 , 3 1 , 3 2 ] .
Moreover these parameters seem to be related to high-
grade transformation, recorded in 1-3% of cases [38,39].
5-year relapse-free survival rate is 65%. Systemic disse-
mination has been observed in 5-10% of cases and only
5% of OAML patients die of lymphoma, with a 5-year
overall survival of > 90% [33,34]. Some cases of sponta-
neous tumor remission in OAML patients have been
reported, mostly in Japanese patients with conjunctival
MALT lymphoma [40].
Histopathology
OAML derives from acquired MALT in orbital region and
from probably native MALT in conjunctive. MALT acqui-
sition is consequent to chronic inflammation due to auto-
immune disorders or infection [41]. Microscopically
neoplastic cells are monocytoid, centrocytic-like or lym-
phoplasmocitoid (Figure 1). OAML are characterized by
prevalence of one of mentioned cell types [30]. In the
regional district containing epithelium such as conjunctive
and lacrimal gland, lymphoepithelial lesions, i.e. lymphoma
cells invasion of epithelial structures, could be observed.
Follicular colonization with lymphoma cells invasion of
germinal centers is sometimes present. Single or clustered
large cells can be also observed. OAML is always asso-
ciated to non-neoplastic cells and reactive secondary
follicles.
Immunoprofile is similar to other MALT lymphoma,
being neoplastic cells CD20+ (Figure 2a), CD79a+, CD3-,
C D 5 - ,C D 1 0 - ,b c l - 6 - ,I g M + ,b c l - 2 + ,C D 4 3 + / - ,C D 2 3 - / + ,
CD21+/-, TCL1+, PAX5+, CD11c+/-, CD35+/-, and IgD-,
cyclin D1-, MUM1- [5,30]. Differential diagnosis of
OAML is generally with other small cells lymphomas,
such as mantle cell lymphoma, follicular lymphoma and
small lymphocytic lymphoma and with reactive lympho-
proliferative disorders. Specific immunohistochemical pro-
file of other low grade lymphomas could help in the
correct diagnosis of OAML, while pseudolymphomatous
proliferation often requires molecular deepening, taking
into account that pathological entities previously classified
as ‘pseudolymphomas’ or ‘benign lymphoid hyperplasia’
are actually considered very rare, since most of them con-
tain clonal B cells [42].
Pathogenesis: General mechanisms and infectious
agents
The MALT lymphomas arise in tissues with native or
acquired MALT. When acquired, it derives from reactive
lymphoid tissue developed to persistent antigenic stimula-
tion, such as chronic inflammation or an autoimmune dis-
order. The nature of inflammatory processes in these
patients is almost always unknown. As Helicobacter pylori
Table 1 Worldwide distribution of Cp infection
Geographical area % Cp+ Reference




East coast USA 35% [15]
Netherlands 29%-0% [15] &[24]
Central Italy 13%-16% [15] &[17]
UK 12% [15]
Southern China 11% [15]
Cuba 10% [16]
Africa 0% [17]
Rochester (New York) 0% [18]
Southern Florida 0% [19] &[21]
North China 0% [20]
Japan 0% [22] &[23]
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lymphomas, other infectious agents have been investigated
in other districts usually sites of MALT lymphomas. Thus
for cutaneous B cell lymphomas Borrelia burgodoferi has
been found associated in a significant subset, especially in
specific geografic areas [10,43-45], while at small intestine
Campylobacter jejuni seems to be responsible of MALT
lymphoma development [9]. Finally for OAML a similar
Figure 1 (a) OAML infiltration of the lacrimal gland, showing squamous metaplasia (H&E) (10×); (b) prevalence of plasmocytoid cells
in OAML (H&E) (40×); (c) prevalence of centrocytic cells around a residual germinal center in OAML (H&E) (40×); (d) prevalence of
monocytoid cells in OAML (H&E) (40×).
Figure 2 CD20 and Bcl10 immunohistochemical expression; (a) Diffuse CD20 staining (60×); (2) High cytoplasmic Bcl10 expression
(40×); (3) High nuclear Bcl10 expression (40×); (d) Negativity for Bcl10 (40×).
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In this context, a B-cell clonal expansion and proliferation
could occur (Figure 3), as indicated by the presence of
somatically hypermutated immunoglobulin genes with an
ongoing mutations pattern. Chronic antigenic stimulation
may induce genetic instability with subsequent chromoso-
mal abnormalities, which, associated with the microen-
vironment, can make the process of clonal growth
independent from antigenic stimulation. In addition
tumor progression to a more aggressive histologic type of
lymphoma (DLBCL) can then be induced by mutations of
tumor suppressor genes such as p53 and p16 [46-49]
(Figure 4).
The geographical difference in incidence of Cp infec-
tion suggests that other agents commonly associated
with chronic eye diseases can play a key role in the
initiation of neoplasia, as Chlamydia abortus [50], Chla-
mydia trachomatis, herpes simplex virus type 1 and 2
and adenovirus type 8 and 19 [29,51].
C. pneumonia infection hasb e e nh y p o t h e s i z e dt ob e
casually associated with different types of malignancies,
including cutaneus T-cell lymphoma [52,53], and lung
cancer [54], but also B cell lymphomas. Infact C. pneu-
monia DNA has been detected in a Chinese patient with
bilateral orbital MALT lymphoma and then associated
with Helicobacter pylori (Hp) in a French patient
[53,55]. Hp infection has been also detected in one third
of a series of Italian OAML patients and in a series of
15 Korean patients with conjunctiva MALT lymphoma
[56,57]. However the association between Hp infection
and OAML remains controversial [58]. In fact Sjo et al.
failed to identify association between Hp infection and
13 analyzed cases of conjunctival MALT lymphoma
through immunohistochemistry and nested polymerase
chain reaction (PCR) techniques [30,59,60]. Finally there
is increasing molecular and epidemiological evidence of
the pathogenetic role of Hepatitis C virus in hepatitis C-
associated OAML. Two Italian studies showed HCV ser-
opositivity in 13-36% of patients OAML, which seemed
to be associated with more aggressive disease than
HCV-negative patients [61,62].
Chlamydia psittaci in OAML
Chlamydia psittaci is an obligate intracellular bacterium
causing pulmonary psittacosis in humans and Chlamy-
diosis in the avians, including pneumonitis, pericarditis,
conjunctivitis, air sacculitis, peritonitis and hepatosple-
nomegaly [63]. The human psittacosis is generally
caused by exposure to infected animals. Morphologically
Chlamydophila can present in three different forms: ele-
mentary body (EB), reticulate body (RB) and intermedi-
ate body (IB). The EB is a small spherical body, of about
Figure 3 Schematic representation of lymphomagenesis potentially induced by Chlamydia psittaci (Cp) in acquired MALT with
follicular germinal center (A) with consequent clonal selection, characterized by clonal expansion of marginal zone lymphoid cells
invading (B) and then replacing germinal center (C).
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tron-dense nucleoid, at the periphery and separated
from an electron-dense cytoplasm. The EB is the infec-
tious form, which attaches to the target cell and finally
enters it. After entering the host cell, the EB takes the
shape of RB (0.5-2.0 mm), which is the metabolically
active intracellular form. In the transition from one
form to another, an intermediate form IB, measuring
about 0.3-1.0 mm, could be observed [63]. Using a com-
bination of PCR and immunohistochemistry, Ferreri
et al. detected Cp DNA in 87% of OAML cases in a
Northern Italy series, establishing an association
between infection of Cp and the OAML [11]. Later, the
same group of authors provided further evidences that a
complete or partial regression was achieved in some
cases of ocular adnexal MALT lymphoma, including
cases negative for Cp, following anti-chlamidial antibio-
tic therapy [11,12,20,64]. Similar findings have been
reported from Korean studies, since Cp-DNA was
detected in 79% of patients [13]. Finally high prevalence
of Cp has been observed in Austrian series [14].
A recent study on ocular adnexal MALT lymphoma
cases from six geographic areas showed marked variation
of the association between infection and OAML among
the regions examined, being most frequent in Germany
(47%), followed by the USA (35%), and the Netherlands
(29%), but relatively low in central Italy (13%), the UK
(12%) and southern China (11%) [15]. Low prevalence
(10%) of Cp infection was also found in cases from Cuba
[16]. Moreover studies from the South Florida and
Rochester (New York) areas of the USA, Netherland,
Japan, Africa and Northern China, France have reported
absence of the association between Cp infection and
OAML [17-25]. Another recent study comparing cases of
Central Italy and African OAML underlines a low fre-
quency of Cp infection in Italian series, accounting
almost 16% of cases, and absence of Cp infection in Afri-
can cases [17]. All these findings suggest that there is a
geographic variability for Cp association and OAML and
that other etiological factors may be involved in the
development of this lymphoma [17].
Recently the role of Cp has been proposed in the patho-
genesis of other non gastrointestinal MALT, since Cp
DNA has been recently evidenced as in all tested lung
MALT lymphomas, in 30% of thyroid MALT lymphomas,
25% of skin MALT lymphomas and 13% of salivary gland
MALT lymphomas. Moreover Cp has been revealed in
41% of the autoimmune disease Sjögren syndrome and
Hashimoto thyroiditis, as potential precursor of specific
subsets of MALT lymphomas. A potential, direct cancero-
genic role of Cp has been suggested. In fact, these micro-
organisms, which establish persistent infections, are
Figure 4 Schematic representation of OAML biological progression from Cp-clonal selection (A) to lymphoma with chromosomal
aberration (B) and finally to histological progression to Diffuse Large B cell Lymphomas (C). Antibiotic therapy could be efficacy only in
the phase of CP antigen dependent growth.
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infected cells [66] and induce polyclonal cell proliferations
in vivo [67,68].
Heat-shock proteins produced by Cp may trigger
immune responses, both humoral and cell-mediated,
which can generate a cross-reactivity against human pro-
teins and other self antigens [69]. This phenomenon may
contribute to alter local tolerance, leading to chronic sti-
mulation by antigens [70]. The role of Cp is not only
restricted to lymphoid proliferation induction, but it
seems to be responsible of chromosomal aberration, prob-
ably due to its mitogenic activity or indirectly induced oxi-
dative damage [26,65]. As in gastric MALT lymphomas t
(11;18) were significantly associated with CagA-positive
strains of H pylori, probably due to oxidative damage on
DNA induced by CagA-positive strains of Hp y l o r i ,i n
OAML could be suggested the same phenomenon [26]. In
fact some infectious agents, as H pylori strains harboring
the CagA island, cause a potent neutrophil activation
through interleukin-8 activity [71]. Finally neutrophils acti-
vation is responsible of oxygen-reactive release, causing
DNA damage, as double-strand breaks [72]. Whatever the
mechanism responsible for chromosomal aberration
occurs, the clonal expansion would virtually become inde-
pendent of antigenic stimulation. Thus frequently infec-
tious agents are not detected in MALT lymphomas with
chromosomal aberrations [20]. In fact in gastric MALT
lymphomas the presence of t(11;18)(q21;q21) correlates
with resistance to antibiotic therapy, since neoplastic pro-
liferation has become independent from infectious disease
[73-75]. In addition, relative unfrequent positivity of Cp
DNA in diffuse large B-cell lymphomas respect to OAML,
is probably consistent with the possibility that the Cp can
lead marginal zone lymphomas to progress to a more
aggressive histotype (i.e., diffuse large B-cell lymphomas),
which is no longer responsive to (and dependent on) the
antigenic stimulation provided by the microorganism [11].
Genetic aberration
Recurrent genetic abnormalities have been described in
extranodal MALT lymphomas. Trisomy of chromosome
3 and chromosome 18 are observed in up to 68% and
57% of patients, respectively [27,57,76-78]. Gain of chro-
mosome 3 has been shown to be more common in orbi-
tal, than in lacrimal gland and conjunctival OAML [76].
Trisomy of chromosome 18, instead, is more frequent in
the conjunctival OAML and predominantly affects young
women [78]. Comparative genomic hybridization (CGH)
carried out in 10 OAML cases showed recurrent chromo-
somal gains at 6p21 and 9q33-qter, in addition to trisomy
3, 12 and 18 [79].
One of the most frequent translocation in MALT lym-
phoma is t (11;18) (q21;q21) (Figure 5a). It is demon-
strated in 10-50% of gastric MALT lymphomas, whereas
this translocation rarely occurs in non-gastric MALT lym-
phomas, with the exception of pulmonary MALT lympho-
mas [27]. Translocation fuses the N-terminal region of the
API2 (apoptosis inhibitor 2) gene (located at chromosome
11) to the C-terminal region of the MALT1 gene (located
at chromosome 18), creating the API2-MALT1 chimeric
fusion protein [80-83], which gains the ability to activate
the NF-kB pathway [84,85]. However the most common
translocation in ocular adnexal MALT lymphomas is the t
(14;18) (q32;q21) (Figure 5b), which seems to be one of
the main pathogenic mechanisms leading to reduced
apoptotic activity, resulting in uncontrolled expression of
MALT1 by bringing the MALT1 gene under the control
of the IGH enhancer, a mechanism similar to that used by
t(1;14). Also t(1;14) (p22;q32) (Figure 5c) does not form a
fusion gene, but rather brings the entire coding region of
the BCL10 gene on chromosome 1 under the control of
the enhancer region of IGH gene on chromosome 14,
leading to uncontrolled expression of the BCL10 gene
[86]. Bcl10 is an intracellular protein that is essential for
both the development and function of mature B and T
cells. Recent studies show that BCL10 specifically links
antigen receptor signaling in B and T cells to NF-kB acti-
vation [87,88]. In MALT lymphomas arising at gastroin-
testinal locations, it is claimed that MALT1, with or
without bcl10 cooperation, activates the phosphorylation
cascade, leading to IkB-a phosphorylation. IkB-a is a phy-
siological ligand of NF-kB in the cytoplasm, whose phos-
phorylation permits the liberation and migration of NF-kB
into the nucleus, where NF-kB plays its transcriptional
role, up-regulating the expression of cell cycle regulators,
anti-apoptotic proteins, growth factors, negative regulators
of the NF-kB pathway and immunoregolatory cytokines
[89-94].
Initially immunohistochemical evaluation of Bcl10 has
been proposed as a good surrogate marker of transloca-
tions in MALT lymphomas. In fact the nuclear expression
of bcl10 could suggest NF-kB activation after t(11;18)(q21;
q21), t(1;14)(p22;q32), while strong cytoplasmic perinuc-
lear expression seems to be linked to t(14;18)(q32;q21)
[28,89,95-97]. It was later noticed that a certain percentage
of OAML missing t (11;18) [26] or t (1;14) [29] and lym-
phoplasmacytoid lymphomas [98] which lack a specific
Bcl10 translocation showed a moderate nuclear Bcl10
expression. Moreover in another study an association
between weak cytoplasmic Bcl10 expression and transloca-
tion (14;18) has been found in only 3 cases [5].
Recently, FOXP1 (located at 3p14) was identified as a
new translocation partner of IGH (q32) at low frequency
in MALT lymphomas and in DLBCL [99,100].
In another recent study of 29 extragastric MALT lym-
phomas, the cases of ocular adnexal MALT lymphoma
showed the ODZ2-IGH (5;14), JMJD2C-IGH (9;14) new
translocations and two translocations with unknown
Collina et al. Infectious Agents and Cancer 2012, 7:8
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MALT lymphoma has been reported yet another new
translocation, the t(5;11) (q33;p11.2), not previously
described [103].
Recently, another possible mechanism for uncontrolled
NF-kB activation in MALT lymphoma, particularly in the
ocular adnexa, salivary gland and thyroid MALT lym-
phoma, is generated by homozygous deletion of the chro-
mosomal band 6q23 with subsequent loss of the tumor
necrosis factor alpha-induced protein 3 (TNFAIP3, A20)
[104], an essential global NF-kB inhibitor. A20 is also inac-
tivated frequently by somatic mutations [105-107]. In
OAML, A20 inactivation is associated with poor lym-
phoma-free survival [104,105,108,109] and with a range of
chronic inflammatory disorders [110-114].
Treatment
The treatment depends upon the variables related to the
patient (age, autoimmune disorders) and to the disease,
particularly on site, stage and surgical accessibility. Surgi-
cal excision is most appropriate for many stage 1 conjunc-
tival and lachrymal gland MALT lymphomas, especially in
pseudoencapsulated lesions [30]. ‘Wait and watch’ strategy
after surgical resection in patients with stage I disease pro-
duces similar results to those reported with immediate
radiotherapy, in terms of progression, systemic dissemina-
tion, transformation in an advanced stage disease and
death associated with lymphoma, with a 10-year overall
survival of 94% [38]. The localized low grade OAML can
be successfully managed with local radiotherapy. Ocular
complications of radiotherapy, including cataract, retinal
disorder, xerophthalmia and glaucoma, are frequently
reported in patients that have long-term follow up [115].
There are few data in the literature regarding the use of
chemotherapy in patients with OAML. Is it clear that is
more effective administration of individual chemothera-
peutic agents, as chlorambucil or fludarabine, for low-
grade lymphomas, and the combinations of chemotherapy,
as cyclophosphamide, doxorubicin, prednisone and
vincristine, for high grade lymphomas [39,116]. The lar-
gest experience regards chlorambucil, an alkylating agent
largely used in indolent lymphomas. This drug is an active
and well-tolerated therapy for stage I OAML, with a 67-
100% response rate, a 79% complete remission rate, recur-
rence in up to 29% and a 5-year relapse-free survival of
60% [30,97,112]. Immunotherapy includes interferon a
and rituximab (anti-CD20 antibody). Rituximab is a
monoclonal antibody against CD20 positive B cells, which
is being considered as an alternative first line treatment
for localized CD20 positive OAML to avoid the ocular
complications of radiotherapy [117-120]. As for the gastric
MALT lymphoma, antibiotic therapy, aimed to eradicate
the Hp infection, is followed by lymphoma regression in
60-70% of stage IE cases [121]. Thus also for OAML asso-
ciated with Cp infection an antibiotic therapy has been
proposed. Results following first line antibiotic treatment
are variable [122]. Ferreri et al. documented an encoura-
ging response following oral doxycycline for 3 weeks in 4
out of 9 patients with Cp positive OAML [12]. Abramson
et al. showed a clinical response following antibiotic treat-
ment in 3 patients with OAML [123], but Grunberger et
al. did not obtain the same results. In another study 27
patients with OAML were treated with oral doxycycline
[124]. Cp infection positive cases had an overall response
rate of 64%, and also the Cp DNA negative cases showed a
clinical response with a rate of 36%, indicating that doxy-
cycline could be used in most OAML patients, indepen-
dently of the diagnosis of Cp infection [30,64,117]. In a
retrospective analysis of 38 patients with localized OAML,
Kim et al. evaluated the effect of doxycycline for 3 weeks
(12 patients) or 6 weeks (26 patients) [125]. After a median
follow-up of 26.4 months, doxycycline resulted in an over-
all response rate of 47%. Patients treated with doxycycline
for 6 weeks versus 3 weeks tended to have a higher
response rate (54% vs 33%).
Doxycycline may be also a valid therapeutic alternative
in disseminated OAML [126]. 6 patients with dissemi-
nated Cp-positive OAML were treated with doxycycline.
Figure 5 FISH; (a) T (11;18) (100×). Yellow fusion signals (arrow) of API2 (green) and MALT1 (red) translocation; (b) T (14;18) (100×). Yellow
fusion signals (arrow) of IGH (green) and MALT1 (red); (c) T (1;14). (60×) Dual color break Apart rearrangement BCL10 probe. Following the
translocation, there is a split signal.
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eral blood mononuclear cells of the six patients, and after
a median follow-up of 31 months, three patients achieved
an objective response [126].
Conclusions
The diagnosis and therapy of OAML requires a strict mul-
tidisciplinary approach. In this context the presence of Cp
and the occurrence of specific chromosomal aberrations
could add important information in order to better perso-
nalize the therapy. However further insights are needed
about Cp induced lymphomagenesis, in particular with
regard to specific antigens related to lymphoma occur-
rence and the role of the host immunity in lymphoma pro-
gression. Finally the absence of Cp in most patients with
OAML, even in front of a therapeutic response to antibio-
tic-therapy, induces on the one hand to improve the diag-
nostic tool of Cp infection on biological samples from
OAML patients and on the other to seek further infectious
agents potentially responsible of tumor initiation.
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